Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan;31(1):31-42.
doi: 10.1111/exd.14286. Epub 2021 Feb 1.

Melanoma brain metastases: Biological basis and novel therapeutic strategies

Manali Phadke  1 , Alpaslan Ozgun  2 , Zeynep Eroglu  2 , Keiran S M Smalley  1   2
Affiliations
Review

Melanoma brain metastases: Biological basis and novel therapeutic strategies

Manali Phadke et al. Exp Dermatol. 2022 Jan.

Abstract

The development of brain metastases is the deadliest complication of advanced melanoma and has long been associated with a dismal prognosis. The recent years have seen incredible progress in the development of therapies for melanoma brain metastases (MBM), with both targeted therapies (the BRAF-MEK inhibitor combination) and immune checkpoint inhibitors (the anti-CTLA-4, anti-PD-1 combination) showing impressive levels of activity. Despite this, durations of response for these therapies remain lower at intracranial sites of metastasis compared to extracranial metastases and it has been suggested that there are unique features of the brain microenvironment that contribute to therapeutic escape. In this review, we outline the latest research into the biology and pathophysiology of melanoma brain metastasis development and progression. We then discuss the current status of clinical trial that are open to patients with MBM and end by describing the ongoing challenges for the field.

Keywords: CNS; brain metastases; immunology; melanoma; metabolism.

PubMed Disclaimer

References

REFERENCES

    1. Tsao H, Chin L, Garraway LA, Fisher DE. Melanoma: from mutations to medicine. Gene Dev. 2012;26(11):1131-1155. https://doi.org/10.1101/Gad.191999.112
    1. Fife KM, Colman MH, Stevens GN, et al. Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol. 2004;22(7):1293-1300. https://doi.org/10.1200/JCO.2004.08.140
    1. Patchell RA. The management of brain metastases. Cancer Treat Rev. 2003;29(6):533-540. https://doi.org/10.1016/S0305-7372(03)00105-1
    1. Chen G, Davies MA. Emerging insights into the molecular biology of brain metastases. Biochem Pharmacol. 2012;83(3):305-314. https://doi.org/10.1016/j.bcp.2011.09.012
    1. Holbrook K, Lutzky J, Davies MA, et al. Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: a case series. Cancer. 2020;126(3):523-530. https://doi.org/10.1002/cncr.32547

Publication types

MeSH terms

Substances

LinkOut - more resources